Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice

Abstract

Tc, for the potential use as radiopharmaceuticals for diagnostic imaging of breast cancer. Methods:The conjugation was achieved in high yield using standard peptide coupling reactions between an amino modification on the aptamer and the activated carboxylic group on the ligands. The retention of the affinity of the MAG2 modified AptA for the MUC1 protein core was confirmed using a FID binding assay. The 2 labelled aptamers were separated from free 99m Tc using microcon filter separation and monitored by HPLC at all stages, to ensure that only radiolabelled aptamers were produced. The biodistribution properties of the two aptamer-radionuclide conjugates were analysed in MCF-7 tumour bearing mice and compared. Tc. The radiolabelled aptamers showed different tumour uptake and clearance, but will require further development prior to diagnostic use. Results

Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice

“…An increasing accumulation of radiolabelled aptamer in time (up to 5 h p.i.) has been often observed with other aptamers [19,20,[47][48][49].…”

Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations

“…[21][22][23] These aptamers have been selected against the APDTRPAPG synthetic peptide of the MUC1 tandem repeat sequence using traditional SELEX approaches. The structure of this anti-MUC1 aptamer has also been studied by nuclear magnetic resonance 33 and deposited in Protein Data Bank.…”

“…21 In addition, they have been capable of detecting circulating MUC1 in sandwich enzyme-linked immunosorbent assays, improving current detection limits, 19 and have been extensively studied as radiopharmaceuticals for their potential in gamma-camera and single-photon emission computed tomography (SPECT) imaging. [21][22][23] Furthermore, they have been shown to be particularly promising agents in photodynamic therapy as phototoxic agents 24 and delivery agents of standard chemotherapy such as doxorubicin. 25 Finally, the MUC1 aptamers have been successfully used in nanoparticle (NP) formulation, described both from our own group 26 for silica NPs and from a different group for liposomal formulation in conjunction with paclitaxel.…”

Aptamers in the Diagnosis of Rickettsiosis Sensu Lato

“…This is achieved through the radiolabelling of antibiotics or other modalities and their subsequent use as imaging agents. Aptamers have already been used as specific antibiotic agents against Salmonella, enterococci and anthrax, and they have been previously described in molecular imaging techniques, labelled with radionuclides (Borbas et al 2007, DaPieve et al 2009, for the diagnostic imaging of disease. Thus, they have clearly the potential for selection against rickettsias and use in nuclear medicine techniques to provide more specific information about both the presence and the fate of the bacteria in the body.…”